View:
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G-A
(Rule 13d-102)
Information Statement Pursuant to Rules 13d-1 and 13d-2
Under the Securities Exchange Act of 1934
(Amendment No. 6)*
ImmunoGen Incorporated
---------------------------------------------------------------
(Name of Issuer)
Common Stock
----------------------------------------------------------------
(Title of Class of Securities)
45253H101
-----------------------------
(CUSIP Number)
*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter
disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
- ------------------------- ---------------------------
|CUSIP NO. 45253H101 | 13G | Page 2 of 4 Pages |
| ----------- | | --- --- |
- ------------------------- ---------------------------
|--------|---------------------------------------------------------------------|
| 1 | NAME OF REPORTING PERSON |
| | S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON |
| | |
| | Aeneas Venture Corporation |
|--------|---------------------------------------------------------------------|
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [ ] |
| | (b) [ ] |
| | |
|--------|---------------------------------------------------------------------|
| 3 | SEC USE ONLY |
| | |
|--------|---------------------------------------------------------------------|
| 4 | CITIZENSHIP OR PLACE OF ORGANIZATION |
| | |
| | Delaware |
|--------|-----------------|--------|------------------------------------------|
| | 5 | SOLE VOTING POWER |
| | | 1,178,659 shares |
| NUMBER OF |--------| -----------------------------------------|
| SHARES | 6 | SHARED VOTING POWER |
| BENEFICIALLY | | -- |
| OWNED BY ----------------------------------------------------|
| EACH | 7 | SOLE DISPOSITIVE POWER |
| REPORTING | | 1,178,659 shares |
| PERSON ----------------------------------------------------|
| WITH | 8 | SHARED DISPOSITIVE POWER |
| | | -- |
|--------|---------------------------------------------------------------------|
| 9 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON |
| | |
| | 1,178,659 shares |
|--------|- -------------------------------------------------------------------|
| 10 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN [ ] |
| | SHARES* |
| | |
|--------|- -------------------------------------------------------------------|
| 11 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) |
| | 6.9% |
|--------|- -------------------------------------------------------------------|
| 12 | TYPE OF REPORTING PERSON * |
| | EP |
- --------------------------------------------------------------------------------
*SEE INSTRUCTIONS BEFORE FILLING OUT!
SCHEDULE 13G
------------
Item 1(a) Name of Issuer:
ImmunoGen Incorporated
1(b) Address of Issuer's Principal Executive Offices:
333 Providence Highway
Norwood, MA 02062
Item 2(a) Name of Person Filing:
Aeneas Venture Corporation
2(b) Address of Principal Business Office or, if none, Residence:
c/o Harvard Management Company, Inc.
600 Atlantic Avenue
Boston, MA 02210
2(c) Citizenship:
Delaware
2(d) Title of Class of Securities:
Common Stock
2(e) CUSIP Number:
45253H101
Item 3 If this statement is filed pursuant to Rules 13d-1(b), or
13d-2(b):
The entity filing is a wholly-owned subsidiary of the
endowment fund of Harvard University.
Item 4 Ownership:
4(a) Amount beneficially owned:
1,178,659 shares, including 10,000 shares which
Aeneas Venture Corporation has the right to acquire pursuant
to options that it holds.
4(b) Percent of Class:
6.9%
4(c) Number of shares as to which such person has:
(i) sole power to vote or to direct the vote:
1,178,659 shares
Page 3 of 4 Pages
(ii) shared power to vote or to direct the vote:
---------
(iii) sole power to dispose or to direct the disposition of:
1,178,659 shares
(iv) shared power to dispose or to direct the disposition of:
--------
Item 5 Ownership of Five Percent or Less of a Class:
Not Applicable.
Item 6 Ownership of More than Five Percent on Behalf of Another Person:
Not Applicable.
Item 7 Identification and Classification of the Subsidiary which
Acquired the Security Being Reported on by the Parent Holding
Company:
Not Applicable.
Item 8 Identification and Classification of Members of the Group:
Not Applicable.
Item 9 Notice of Dissolution of Group:
Not Applicable.
Item 10 Certification:
By signing below the undersigned certifies that, to the best of
its knowledge and belief, the securities referred to above were
acquired in the ordinary course of business and were not acquired
for the purpose of and do not have the effect of changing or
influencing the control of the issuer of such securities and were
not acquired in connection with or as a participant in any
transaction having such purpose or effect.
After reasonable inquiry and to the best of its knowledge and belief, the
undersigned certifies that the information set forth in this statement is true,
complete and correct.
AENEAS VENTURE CORPORATION
By: /s/ Tami E. Nason
-------------------------------
Name: Tami E. Nason
Title: Authorized Signatory
February 12, 1997
Page 4 of 4 Pages